Overview
Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.
Lobbying Costs
None declared
Financial year: Jan 2022 - Dec 2022
Lobbyists (Full time equivalent)
1.3 Fte (5)
Lobbyists with EP accreditation
0
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
European Society of Endocrinology (ESE)
EU Transparency Register
270225149770-57 First registered on 11 Apr 2023
Goals / Remit
The European Society of Endocrinology is at the centre of Europe's endocrine community. It is our vision to shape the future of endocrinology to improve science, knowledge and health. It is our mission to advance endocrinology. We unite, support and represent our specialty, promoting collaboration and best practice, and enable our community to develop and share the best knowledge in endocrine science and medicine.
Through the 50 National Societies involved with the ESE Council of Affiliated Societies (ECAS) ESE represents a community of over 22,000 European endocrinologists. We inform policy makers on health and research policy decisions through advocacy efforts across Europe.Main EU files targeted
• Classification Labelling and Packaging regulation (CLP).
• Registration, Evaluation, Authorisation and Restriction of Chemicals Regulation (REACH).
• Chemicals Strategy for Sustainability.
• European Beating Cancer Plan.
• European Health Data Space (EHDS).
• In Vitro Diagnostic Medical Devices Regulation (IVDR).Address
Head Office
Redwood House Brotherswood Court, Great Park Road Almondsbury Business Park, Bradley Stoke
Bristol BS32 4QW
UNITED KINGDOMEU Office
Redwood House Brotherswood Court, Great Park Road Almondsbury Business Park, Bradley Stoke
Bristol BS32 4QW
UNITED KINGDOMWebsite
-
People
Total lobbyists declared
5
Employment time Lobbyists 50% 2 10% 3 Lobbyists (Full time equivalent)
1.3
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
0 accreditations were / are live (in bold) for the selected state of 05 May 2023
Name Start date End Date Michael VAN EIMEREN 26 May 2023 24 May 2024 Mr Mischa van Eimeren 26 May 2023 30 May 2023 Complementary Information
These people represent ESE staff. Beyond these specific staff ESE has created internal structures to develop its policy and advocacy approach. These structures build on the voluntary engagement of clinical and basic research experts engaged in different committees of the organisation (Executive Committee, Policy and Advocacy Taskforce and working groups, European Council of Affiliated Societies).
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Non-governmental organisations, platforms and networks and similar
-
Networking
Affiliation
The Alliance for Biomedical Research in Europe (Biomed Alliance): https://www.biomedeurope.org/
European Cancer Organisation: https://www.europeancancer.org/Member organisations
ESE has formal affiliations with 50 National endocrine societies across geographical Europe as 12 specialist partner societies, dedicated to their respective and specific fields of endocrinology. A full list of societies can be found here: https://www.ese-hormones.org/about-us/our-communities/ese-council-of-affiliated-societies/
ESE also has formal affiliations with 24 Patient Advocacy and support groups covering the diverse spectrum of endocrinology disease: https://www.ese-hormones.org/membership/membership-information/other-memberships/patient-advocacy-group-affiliated-membership/ -
Financial Data
Interests represented
Does not represent commercial interests
Closed financial year
Jan 2022 - Dec 2022
Lobbying costs for closed financial year
Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.
Total organisational budget in closed year
4,309,295€
Major funding types in closed year
Member's contribution
Major contributions in closed year
Type Name Amount Contribution Abiogen 118,000€ Contribution HRA Pharma 230,000€ Contribution Ipsen 190,000€ Contribution Novo Nordisk 128,500€ Contribution Pfizer 166,000€ Contribution Recordati Rare Diseases 177,500€ Contribution Takeda 145,000€ Contribution Ace Pharmaceuticals 48,000€ Contribution Alexion Pharma 40,000€ Contribution Ascendis 47,000€ Contribution Consilient Health 32,000€ Contribution CORE2ED - for Rare Bone Disease Pharmaceutical Consortium 85,000€ Contribution Crinetics Pharmaceuticals 18,000€ Contribution Diurnal 57,500€ Contribution International Medical Press 60,000€ Contribution Kyowa Kirin International 99,050€ Contribution Soleno Therapeutics 21,750€ Contribution Uni-Pharma 53,750€ Other financial info
Our income is derived from:
Sponsorships, annual Congress, publications income, membership subscriptions, rebates and commissions, investment income, annual meetings and events. -
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
1. European Hormone Day 'Because Hormones Matter' - Building Public and Policy Awareness for the Role of Hormones in Public Health - 15 May 2023.
2. Response to consultations in the field of the policies listed above.
(CLP Regulation, BPA, European Health Data Space and others).
3. Publication of the White Paper Hormones in European Health Policies, How Endocrinologist can contribute towards a healthier Europe (May 2021).
4. Publication of 'the Milano Declaration' Recognising the Key Role of Hormones European Health (May 2022).
5. Publication of 'Ten recommendations for Good Hormone Health' Annex of the Milano Declaration (May 2023).
6. Participation to the Annual EDC Forum (Brussels, Sept 2022).
7. Engagement with European Commission related to the REACH Legislative Proposal (March 2023).Other activities
None declared
Meetings
Meetings
None declared